Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.

Exclusion Criteria

• •1. Any X-ray film that documents substantial scoliosis, or spinal secondary osteoporosis;
• •2. Any X-ray film that documents bone fracture within 3 month prior to the trial.
• •3. Medication such as estrogen, bisphosphonates, calcitonin, fluoride, glucocorticoids, ipriflavone intake within 3 weeks prior to the trial;
• •4. Use of other Chinese medicine within 2 weeks prior to the trial;
• •5. Patients with significant renal function impairment (Creatinine\>2mg/dl) and liver function impairment (AST and ALT \> 2 x the upper limit of normal range);
• •6. Patients have laboratory test abnormality, which in the investigator's opinion might confound the study;
• •7. Patients have severe cardiac disease, e.g. unstable angina pectoris, myocardial infarction, congestive heart failure (New York Heart Association Functional Classification III and IV);
• •8. Patients have life threatening disease;
• •9. Patients are allergic to any of the composition of Chinese medicine;
• •10. Significant concomitant disease or medical history that could interfere with the study as judged by the investigator;